Cefuroxime Uses 9 Powerful Benefits, Medical Uses & Important Risks You Must Know

Cefuroxime Uses: 8 Powerful Facts About Cefuroxime Axetil, Ceftin, Zinnat & Zinacef

What if one of the most versatile antibiotics in clinical medicine could be hiding in plain sight — quietly treating everything from sinus infections to Lyme disease — while many clinicians still underestimate its full pharmacological potential?

That antibiotic is cefuroxime, and it has been earning its place in hospital formularies and outpatient prescriptions since 1987. But here is what makes it genuinely fascinating: cefuroxime exists in two distinct chemical forms — an oral prodrug called cefuroxime axetil (sold as Ceftin and Zinnat) and a parenteral sodium salt (sold as Zinacef) — each with unique pharmacokinetic properties that dramatically affect how they are used in clinical practice.

Different antibiotics work against different bacteria, reach different tissues, have different pharmacological properties, and carry different risks. The appropriate choice depends on the suspected or confirmed organism, site and severity of infection, local resistance patterns, allergies, kidney and liver function, drug interactions, and patient-specific considerations. But cefuroxime occupies a particularly interesting niche: it is a second-generation cephalosporin that bridges the gap between narrow-spectrum agents and broader third-generation options.

What you are about to read will challenge the way you think about this drug. We will explore 8 powerful facts about cefuroxime — from its FDA-approved indications and dosage strategies to its spectrum of activity, resistance challenges, and the latest evidence from clinical studies. Whether you are a medical student preparing for ward rounds, a practicing clinician refining your antimicrobial stewardship, or a pharmacist ensuring safe dispensing, the clinically important details in this article will strengthen your understanding of this remarkable antibiotic. Stay with us — because the details that make cefuroxime truly powerful are revealed progressively.

A sobering clinical reality first: adverse drug reactions account for a significant proportion of hospital admissions, and beta-lactam antibiotics like cefuroxime are among the most commonly implicated drug classes. Understanding the full safety profile is not optional — it is essential. For a suspenseful, evidence-based look at this hidden crisis, explore Shocking Adverse Drug Reaction Facts before you prescribe another beta-lactam.

Key Facts Table: Cefuroxime at a Glance

The following table summarizes the most clinically important facts about cefuroxime. This is not a substitute for full prescribing information, but it provides a rapid reference for healthcare professionals and students.

This table is a snapshot. Every parameter in it will be expanded in the dedicated sections below, but we will not repeat the full explanations unnecessarily.

FDA-Approved Uses

The U.S. Food and Drug Administration (FDA) has granted cefuroxime axetil approval for a well-defined set of clinical indications, each supported by adequate and well-controlled trials. Understanding these approved uses is essential for appropriate prescribing and antimicrobial stewardship. This section details what is cefuroxime used for from an FDA standpoint, along with pathogen and dosing details.

• Pharyngitis/Tonsillitis (Adults and Pediatric Patients):
  Cefuroxime axetil tablets are indicated for the treatment of mild-to-moderate pharyngitis/tonsillitis caused by susceptible strains of Streptococcus pyogenes. Dosage: Adults and adolescents 13 years and older — cefuroxime 250 mg every 12 hours for 10 days. This indication is particularly relevant because group A streptococcal pharyngitis requires complete eradication to prevent rheumatic fever.
• Acute Bacterial Otitis Media (Pediatric Patients):
  One of the most common pediatric infections requiring antibiotic therapy. Cefuroxime axetil is FDA-approved for this indication. Dosage: Children younger than 13 years who can swallow tablets — 250 mg every 12 hours for 10 days; oral suspension — 30 mg/kg/day divided twice daily, maximum 1,000 mg/day. Cefuroxime covers the major pathogens responsible for otitis media, including Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.
• Acute Bacterial Maxillary Sinusitis (Adults and Pediatric Patients):
  A dedicated clinical trial demonstrated that cefuroxime axetil 250 mg twice daily produced clinical success rates of 65% in U.S. subjects and 77% in South American subjects, with clinical cure rates of 53% and 72%, respectively. Microbiology data demonstrated effectiveness in sinusitis due only to Streptococcus pneumoniae or non-beta-lactamase-producing Haemophilus influenzae. Insufficient numbers of beta-lactamase-producing H. influenzae and M. catarrhalis isolates were obtained to adequately evaluate effectiveness against these organisms.
• Acute Bacterial Exacerbations of Chronic Bronchitis (Adults and Pediatric Patients 13 Years and Older):
  For mild-to-moderate exacerbations, Dosage: 250 mg or 500 mg every 12 hours for 10 days. The 500 mg dose is often selected when more resistant organisms are suspected or when the patient has failed prior therapy.
• Uncomplicated Skin and Skin-Structure Infections (Adults and Pediatric Patients 13 Years and Older):
  Dosage: 250 mg or 500 mg every 12 hours for 10 days. The 500 mg dose is typically reserved for more severe infections or when methicillin-susceptible Staphylococcus aureus is confirmed or suspected.
• Uncomplicated Urinary Tract Infections (Adults and Pediatric Patients 13 Years and Older): 
  Dosage: 250 mg every 12 hours for 7 to 10 days. This covers cystitis caused by susceptible strains of Escherichia coli and Klebsiella pneumoniae. Cefuroxime is not a first-line agent for uncomplicated UTI in most guidelines, but it remains a valuable option when first-line agents are contraindicated or when culture and sensitivity data support its use.
• Uncomplicated Gonorrhea (Adults and Pediatric Patients 13 Years and Older):
  Dosage: A single 1,000 mg oral dose. However, current CDC guidelines recommend ceftriaxone as the preferred treatment for gonorrhea due to emerging resistance patterns. Cefuroxime remains an alternative in specific circumstances where ceftriaxone is unavailable or contraindicated.
• Early Lyme Disease (Adults and Pediatric Patients 13 Years and Older):
  Dosage: 500 mg every 12 hours for 20 days. Two adequate and well-controlled trials demonstrated that cefuroxime axetil and doxycycline were both effective in preventing the development of sequelae of late Lyme disease. This is particularly important for patients who cannot take doxycycline (pregnant women or children under 8 years).
• Impetigo (Pediatric Patients):
  Ceftin (cefuroxime axetil) is indicated for impetigo in pediatric patients. Dosage: Oral suspension 30 mg/kg/day divided twice daily, maximum 1,000 mg/day for 10 days. Provides effective coverage against S. aureus and S. pyogenes.

Off-Label and Guideline-Supported Uses: Beyond FDA-approved indications, cefuroxime has been studied or recommended in guidelines for other infections. The parenteral formulation (Zinacef) has additional FDA-approved indications including bone and joint infections, bacterial meningitis (with dose limitations), and disseminated gonococcal infections. Clinicians must always consider local resistance patterns, culture results, and current guidelines when considering off-label use, and must never label an off-label use as FDA-approved.

Dosage Table

The table below provides a concise summary of typical dosing for common indications. Doses may vary based on renal and hepatic function, severity, and susceptibility data.

Important: Tablets and oral suspension are not bioequivalent and are not substitutable on a milligram-per-milligram basis. Administer tablets with or without food; administer oral suspension with food to enhance absorption.

Mechanism of Action

Cefuroxime exerts its bactericidal effect through a well-characterized molecular mechanism that distinguishes it from many other antibiotic classes. Understanding this mechanism is fundamental to appreciating both its clinical utility and its limitations.

Primary Molecular Target: Cefuroxime, like all beta-lactam antibiotics, targets penicillin-binding proteins (PBPs) — a group of enzymes embedded in the bacterial cytoplasmic membrane that are essential for cell wall synthesis. Specifically, cefuroxime binds to and inhibits PBPs involved in the cross-linking of peptidoglycan chains.

Binding and Interaction: The beta-lactam ring of cefuroxime is structurally analogous to the terminal D-alanyl-D-alanine moiety of peptidoglycan precursors. This molecular mimicry allows cefuroxime to bind covalently to the active site serine residue of PBPs, forming a stable acyl-enzyme complex that irreversibly inhibits transpeptidase activity. Cefuroxime has activity in the presence of some beta-lactamases, both penicillinases and cephalosporinases, of gram-negative and gram-positive bacteria.

Cellular Pathway Affected: By inhibiting PBP-mediated cross-linking, cefuroxime disrupts the final stages of peptidoglycan synthesis. This leads to a weakened cell wall that cannot withstand the internal osmotic pressure of the bacterial cytoplasm. The result is bacterial cell lysis and death — a bactericidal effect. Additionally, cefuroxime may trigger autolysin activation, further contributing to cell wall degradation.

Physiologic and Clinical Consequences: The clinical therapeutic effect of cefuroxime — bacterial killing at the site of infection — depends on achieving adequate free drug concentrations at the target tissue for a sufficient duration. This is why dosing regimens are designed to maintain serum and tissue concentrations above the minimum inhibitory concentration (MIC) for the infecting organism throughout the dosing interval.

Resistance Mechanisms: Resistance to cefuroxime occurs through several mechanisms: hydrolysis by beta-lactamases (including extended-spectrum beta-lactamases, or ESBLs), alteration of penicillin-binding proteins (PBPs), decreased permeability of the outer membrane, and the presence of bacterial efflux pumps. Beta-lactamase-negative, ampicillin-resistant (BLNAR) isolates of H. influenzae should be considered resistant to cefuroxime axetil. Most ESBL-producing and carbapenemase-producing isolates are resistant to cefuroxime axetil.

What Is Cefuroxime?

Cefuroxime is a semisynthetic, broad-spectrum cephalosporin antibiotic belonging to the second generation of this drug class. It was initially approved by the FDA in 1987 and has since become one of the most widely prescribed oral cephalosporins worldwide.

Generic Name and Drug Class: The generic name is cefuroxime. When administered orally, it is formulated as cefuroxime axetil — an ester prodrug that is absorbed intact and then hydrolyzed by esterases in the intestinal mucosa and liver to release active cefuroxime into the systemic circulation. The parenteral formulation uses cefuroxime sodium, which is directly bioavailable after intravenous or intramuscular injection.

Pharmacologic Classification: Cefuroxime belongs to the beta-lactam family of antibiotics. Within the cephalosporin class, it is classified as second-generation based on its spectrum of activity, which bridges the gap between first-generation agents and third-generation agents. Cefuroxime has activity in the presence of some beta-lactamases, making it more stable than first-generation cephalosporins against many beta-lactamase-producing organisms.

Therapeutic Role: Clinically, cefuroxime serves as a versatile oral and parenteral antibiotic for respiratory tract infections, urinary tract infections, skin infections, and specific infections such as early Lyme disease. It is particularly valued for its activity against Haemophilus influenzae (including beta-lactamase-producing strains), Moraxella catarrhalis, and Streptococcus pneumoniae. The World Health Organization classifies cefuroxime in the “Watch” group of its AWaRe classification, indicating it should be used judiciously to preserve its effectiveness.

Formulations, Strengths, and Routes: Oral tablets come in 250 mg and 500 mg strengths. Oral suspension granules are available as 125 mg/5 mL and 250 mg/5 mL formulations. The parenteral form (cefuroxime sodium) is supplied as vials containing 750 mg, 1.5 g, or 7.5 g of powder for reconstitution. The oral route is appropriate for mild-to-moderate infections; the parenteral route is reserved for more severe infections or patients who cannot take oral medications.

Differences from Closely Related Medicines: Cefuroxime differs from first-generation cephalosporins (such as cephalexin) in its enhanced gram-negative activity, particularly against H. influenzae and M. catarrhalis. Compared to third-generation cephalosporins (such as ceftriaxone), cefuroxime has superior activity against gram-positive organisms. For a suspenseful, detailed comparison of another third-generation workhorse, explore Facts About Ceftriaxone Sodium Uses — and see why the two are not interchangeable.

Pharmacokinetics & Pharmacodynamics Key Table

The following table summarizes the key pharmacokinetic (PK) and pharmacodynamic (PD) properties that inform the clinical use of cefuroxime.

This table is a quick reference. The following sections explain the most important details without unnecessary repetition.

Half-Life

The elimination half-life of cefuroxime is a fundamental pharmacokinetic parameter that directly influences dosing frequency and helps clinicians anticipate drug accumulation in specific populations. Under normal renal function, the mean ultimate serum half-life of cefuroxime is approximately 70 minutes (1.2 hours), with a range of 1–2 hours depending on the specific population studied.

This relatively short half-life explains why cefuroxime is dosed every 12 hours for most indications — the dosing interval is designed to maintain serum concentrations above the MIC for the infecting organism throughout the treatment period. In elderly patients, the half-life can be significantly prolonged. A study of 20 elderly subjects (mean age 83.9 years) with a mean creatinine clearance of 34.9 mL/min found that the mean serum elimination half-life was prolonged to 3.5 hours. However, despite the lower elimination of cefuroxime in geriatric patients, dosage adjustment based solely on age is not necessary.

Renal impairment has the most clinically significant impact on cefuroxime half-life. Since cefuroxime is eliminated primarily by the kidneys, any condition that reduces glomerular filtration rate or renal tubular secretion will prolong the half-life and necessitate dosage interval adjustments. For patients with creatinine clearance less than 30 mL/min, the dosage interval should be extended to every 24 hours (for CrCl 10–29 mL/min) or every 48 hours (for CrCl <10 mL/min without hemodialysis).

The clinical significance of half-life extends beyond dosing convenience. A prolonged half-life increases the risk of drug accumulation and toxicity, particularly in patients with renal impairment who may develop seizures if the dosage is not appropriately adjusted. Conversely, an understanding of half-life allows clinicians to predict how quickly a drug will be cleared from the body after discontinuation.

Metabolism

Cefuroxime is characterized by remarkable metabolic stability, a property that simplifies its clinical use and minimizes concerns about hepatic drug interactions. Studies have demonstrated that cefuroxime has a metabolic stability of greater than 95%, meaning that nearly all of the administered drug circulates in its active, unchanged form.

Primary Metabolic Pathway: Unlike many other drug classes that undergo extensive hepatic metabolism, cefuroxime axetil is rapidly hydrolyzed by esterases in the intestinal mucosa and liver to release active cefuroxime. The axetil ester group is cleaved to yield the parent cefuroxime molecule, which then circulates without further significant biotransformation. This ester hydrolysis is not mediated by cytochrome P450 enzymes, which means cefuroxime has minimal potential for CYP-mediated drug interactions.

Major Enzymes and Metabolites: The esterases responsible for cefuroxime axetil hydrolysis are widely distributed in human tissues and are not inducible or inhibitable by other medications to a clinically significant degree. No active metabolites of clinical importance have been identified. The absence of significant hepatic metabolism means that cefuroxime is largely unaffected by hepatic enzyme inducers or inhibitors.

Clinical Relevance: The metabolic stability of cefuroxime has several important clinical implications. First, hepatic impairment does not significantly alter the pharmacokinetics of cefuroxime, and dosage adjustment is generally not required for hepatic dysfunction alone. Second, it reduces the risk of drug-drug interactions mediated through metabolic pathways. Third, it ensures that the active drug is available for antibacterial activity without requiring metabolic activation.

Enzyme Interactions: While cefuroxime itself does not meaningfully inhibit or induce cytochrome P450 enzymes, the co-administration of probenecid — a drug that inhibits renal tubular secretion — increases the area under the serum concentration versus time curve (AUC) and maximum serum concentration (Cmax) of cefuroxime by 50% and 21%, respectively. This interaction occurs at the level of renal excretion rather than hepatic metabolism and can increase the risk of adverse effects.

Bioavailability & Protein Binding

Oral Bioavailability: The oral bioavailability of cefuroxime axetil is one of its most clinically relevant pharmacokinetic properties. When taken on an empty stomach, the absolute bioavailability of cefuroxime axetil is approximately 37%. However, when administered with food, bioavailability increases to approximately 52%. This food effect is attributed to prolonged gastric residence time and enhanced dissolution of the prodrug in the duodenum, where absorption is optimal.

This clinically significant food effect has important implications for patient counseling. Patients should be advised to take cefuroxime axetil tablets with food whenever possible to maximize absorption and ensure adequate serum concentrations for therapeutic efficacy. The oral suspension should always be administered with food. The difference between fasting and fed bioavailability is not merely academic — it can mean the difference between therapeutic success and treatment failure, particularly for infections caused by organisms with higher MIC values.

Factors Affecting Absorption: Several factors can influence the absorption of cefuroxime axetil. Gastric pH, gastrointestinal motility, and the presence of food all play roles. The tablets and suspension are not bioequivalent — the suspension produces higher peak concentrations but may have different absorption characteristics than the tablet formulation.

Protein Binding: Cefuroxime is approximately 33–50% bound to plasma proteins, primarily albumin. This moderate degree of protein binding has several clinical implications. First, it means that a substantial fraction of the drug circulates in the free, pharmacologically active form capable of diffusing into tissues and binding to bacterial PBPs. Second, it means that cefuroxime is not subject to the same degree of drug displacement interactions as highly protein-bound drugs (such as warfarin or phenytoin). Third, in conditions that alter plasma protein concentrations — such as hypoalbuminemia in hepatic disease, nephrotic syndrome, or malnutrition — the free fraction of cefuroxime may increase, potentially enhancing both therapeutic and toxic effects. For a deeper dive into this concept, refer to our detailed guide on plasma protein binding.

Clinical Significance: The combination of moderate bioavailability and moderate protein binding means that cefuroxime achieves predictable and reliable serum concentrations in most patients. However, clinicians should be aware that in critically ill patients with altered gastrointestinal absorption or in those with significant hypoalbuminemia, the pharmacokinetics of cefuroxime may deviate from the norm.

Spectrum of Activity

Understanding the antimicrobial spectrum of cefuroxime is essential for appropriate prescribing and antimicrobial stewardship. As a second-generation cephalosporin, cefuroxime occupies a distinctive middle ground in the cephalosporin family — with activity against both gram-positive and gram-negative organisms that is broader than first-generation agents but more limited than third-generation compounds against certain resistant gram-negative pathogens.

Gram-Positive Activity: Cefuroxime demonstrates reliable activity against methicillin-susceptible Staphylococcus aureus (MSSA), Streptococcus pneumoniae, and Streptococcus pyogenes. It also has in vitro activity against methicillin-susceptible coagulase-negative staphylococci (such as Staphylococcus epidermidis and Staphylococcus saprophyticus) and Streptococcus agalactiae (group B Streptococcus). Notably, cefuroxime is not active against methicillin-resistant Staphylococcus aureus (MRSA), and it should not be used for infections suspected or confirmed to be caused by this organism.

Gram-Negative Activity: The gram-negative spectrum of cefuroxime is one of its defining features as a second-generation cephalosporin. It covers Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae (including beta-lactamase-producing strains), Haemophilus parainfluenzae, Moraxella catarrhalis, and Neisseria gonorrhoeae. This activity against beta-lactamase-producing H. influenzae and M. catarrhalis is particularly important for respiratory tract infections.

However, cefuroxime has important limitations in its gram-negative spectrum. Most extended-spectrum beta-lactamase (ESBL)-producing and carbapenemase-producing isolates are resistant to cefuroxime axetil. Beta-lactamase-negative, ampicillin-resistant (BLNAR) isolates of H. influenzae should be considered resistant. Pseudomonas aeruginosa is intrinsically resistant to cefuroxime and should not be treated with this agent. Enterobacter species, Serratia species, and Citrobacter species may produce inducible AmpC beta-lactamases that confer resistance.

Anaerobic Activity: Cefuroxime has limited anaerobic activity. In vitro data suggest activity against Peptococcus niger and some other gram-positive anaerobes, but the clinical significance of this activity has not been established in adequate and well-controlled trials. For infections where anaerobic coverage is required, cefuroxime should be combined with an appropriate anti-anaerobic agent such as metronidazole.

Atypical Organisms and Spirochetes: Cefuroxime demonstrates activity against Borrelia burgdorferi, the spirochete responsible for Lyme disease — an activity that forms the basis for its FDA-approved indication in early Lyme disease. It does not, however, cover atypical respiratory pathogens such as Mycoplasma pneumoniae, Chlamydia pneumoniae, or Legionella species.

Acquired and Intrinsic Resistance: Intrinsic resistance refers to resistance mechanisms that are inherent to a bacterial species. Pseudomonas aeruginosa, Enterococcus species, and Stenotrophomonas maltophilia are intrinsically resistant to cefuroxime. Acquired resistance occurs when previously susceptible organisms develop resistance mechanisms, most commonly through the acquisition of beta-lactamase enzymes (including ESBLs and AmpC beta-lactamases), alterations in penicillin-binding proteins, decreased outer membrane permeability, or efflux pump upregulation.

Susceptibility Testing: The clinical utility of cefuroxime for any given infection ultimately depends on the susceptibility of the infecting organism. The Clinical and Laboratory Standards Institute (CLSI) and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) have established MIC breakpoints for cefuroxime against various organisms. Clinicians should always consult local susceptibility data when available, as resistance patterns vary geographically and temporally. Importantly, in vitro activity does not automatically translate to clinical effectiveness.

Pharmacodynamics

The pharmacodynamics of cefuroxime — how the drug exerts its effects on bacteria — provides the scientific rationale for dosing strategies and explains why certain dosage regimens are more effective than others.

Drug-Target Interaction: Cefuroxime’s primary pharmacodynamic action is inhibition of penicillin-binding proteins (PBPs), leading to disruption of peptidoglycan cross-linking and bacterial cell lysis. The drug exhibits bactericidal activity — it kills bacteria rather than merely inhibiting their growth — which is a desirable property for treating serious infections, particularly in immunocompromised patients where bacteriostatic agents may be insufficient.

Concentration-Response Relationship and Time-Dependent Killing: Beta-lactam antibiotics, including cefuroxime, exhibit time-dependent killing. This means that the extent of bacterial killing is primarily determined by the duration of time that the free drug concentration remains above the minimum inhibitory concentration (MIC) for the infecting organism, rather than by peak concentration. The PK/PD index that best correlates with efficacy for beta-lactams is the percentage of the dosing interval during which the free drug concentration exceeds the MIC (%T > MIC).

For cefuroxime, preclinical and clinical studies suggest that optimal bactericidal activity is achieved when free drug concentrations remain above the MIC for at least 40–70% of the dosing interval. This pharmacodynamic principle explains why cefuroxime is administered on a twice-daily schedule rather than as a single large dose.

Therapeutic Window: The therapeutic window for cefuroxime — the range between effective and toxic concentrations — is relatively wide for most patients. However, the upper limit of the therapeutic window is relevant in patients with renal impairment, where drug accumulation can lead to concentrations high enough to cause neurotoxicity (including seizures). This is why dosage interval adjustment is mandatory for patients with creatinine clearance less than 30 mL/min.

Post-Antibiotic Effect: Cefuroxime demonstrates a post-antibiotic effect (PAE) against certain organisms, meaning that bacterial growth remains suppressed even after drug concentrations fall below the MIC. The PAE for cefuroxime is modest compared to agents like aminoglycosides, but it does contribute to the efficacy of intermittent dosing regimens. The PAE is most pronounced against gram-positive organisms and is shorter or absent against gram-negative bacilli.

Resistance Suppression: Maintaining adequate drug concentrations throughout the dosing interval not only maximizes bacterial killing but also suppresses the emergence of resistant mutants. Sub-therapeutic drug concentrations — which can occur when patients miss doses or take cefuroxime without food (reducing bioavailability from 52% to 37%) — can expose bacteria to sub-inhibitory antibiotic concentrations, creating selective pressure for resistant strains. This is a critical consideration for antimicrobial stewardship.

Contraindications

Absolute Contraindications: Cefuroxime axetil is contraindicated in patients with known hypersensitivity to cefuroxime axetil or to other beta-lactam antibiotics, including penicillins and cephalosporins. This is an absolute contraindication because cross-reactivity between penicillins and cephalosporins, while uncommon, can result in severe hypersensitivity reactions including anaphylaxis. The risk of cross-reactivity is estimated to be approximately 1–2% for second-generation cephalosporins.

Major Hypersensitivity Contraindications: Patients with a history of severe immediate hypersensitivity reactions to penicillins — including anaphylaxis, angioedema, or bronchospasm — should not receive cefuroxime unless the clinical situation warrants the risk and appropriate precautions are in place. In such cases, consultation with an allergist or infectious disease specialist is recommended.

Disease-Specific Contraindications: There are no absolute contraindications based on specific disease states in the FDA labeling. However, cefuroxime should be used with caution in patients with a history of gastrointestinal disease, particularly colitis, because of the risk of Clostridioides difficile-associated diarrhea (CDAD). Cefuroxime is not contraindicated in renal impairment, but dosage interval adjustment is required.

Formulation-Specific Contraindications: The oral suspension formulation of Ceftin contains phenylalanine and should not be used in patients with phenylketonuria. Patients with known hypersensitivity to any excipient in the formulation should not receive that specific product.

Warnings & Precautions

• Serious Hypersensitivity Reactions: Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving beta-lactam antibiotics, including cefuroxime. These reactions are more likely to occur in individuals with a history of penicillin hypersensitivity. Before initiating cefuroxime therapy, clinicians should inquire carefully about previous hypersensitivity reactions. If an allergic reaction occurs, cefuroxime should be discontinued immediately and appropriate supportive measures instituted.
• Clostridioides difficile-Associated Diarrhea (CDAD): CDAD has been reported with the use of nearly all antibacterial agents, including cefuroxime, and may range in severity from mild diarrhea to fatal colitis. CDAD should be considered in all patients who present with diarrhea following antibiotic use. If CDAD is suspected or confirmed, cefuroxime should be discontinued and appropriate treatment initiated.
• Renal Impairment: Since cefuroxime is eliminated primarily by the kidneys, patients with impaired renal function are at risk of drug accumulation. A dosage interval adjustment is required for patients whose creatinine clearance is less than 30 mL/min. In patients with severe renal impairment who receive standard doses without adjustment, high serum concentrations of cefuroxime can lead to neurotoxicity, including seizures.
• Hepatic Impairment: Although cefuroxime undergoes minimal hepatic metabolism, transient rises in serum liver enzymes or bilirubin have been observed, particularly in patients with pre-existing hepatic disease. These elevations are usually reversible and rarely necessitate discontinuation of therapy.
• Pregnancy and Breastfeeding: Cefuroxime axetil should be used during pregnancy only if clearly needed. Cefuroxime is excreted in human milk in small quantities, and caution should be exercised when administering cefuroxime to a nursing woman. A case of diarrhea was reported in 2.6% of cefuroxime-exposed infants.
• Pediatric Use: The safety and efficacy of cefuroxime axetil in pediatric patients younger than 3 months have not been established. For pediatric patients 3 months to 12 years, the oral suspension is the preferred formulation.
• Older Adults: In a trial of 20 elderly subjects (mean age 83.9 years) with reduced creatinine clearance, the mean serum elimination half-life was prolonged to 3.5 hours. However, dosage adjustment based solely on age is not necessary; dosing should be based on renal function.
• Drug Interactions: Concomitant administration of probenecid with cefuroxime axetil increases serum concentrations of cefuroxime and is not recommended. As with all antibiotics, cefuroxime may reduce the effectiveness of oral contraceptives, though the magnitude of this interaction is debated.
• Monitoring Requirements: Routine monitoring of renal function is recommended in patients with pre-existing renal impairment or those receiving concomitant nephrotoxic drugs. Clinical monitoring for signs of hypersensitivity, CDAD, and neurotoxicity (particularly in patients with renal impairment) is essential throughout therapy.

Side Effects

Understanding the side effect profile of cefuroxime is essential for patient counseling and clinical monitoring. Adverse effects are broadly categorized by frequency, and distinguishing between common, bothersome side effects and serious adverse reactions is clinically important.

Common Side Effects:

• Diarrhea or loose stools (approximately 1% to 10% of patients) — the most common complaint.
• Nausea and vomiting, particularly when the medication is taken on an empty stomach.
• Abdominal cramps or discomfort (0.1% to 1% of patients).
• Headache and dizziness.
• Vaginal candidiasis (yeast infections) due to disruption of normal vaginal flora.
• Transient eosinophilia and mild elevations in liver enzymes (most commonly observed laboratory abnormalities).

Less Common Side Effects:

• Oral candidiasis (thrush), particularly in immunocompromised patients or those receiving prolonged courses.
• Rash, urticaria, and pruritus (fewer than 1% of patients) — may indicate hypersensitivity.
• Vaginitis and genital candidiasis.
• Transient neutropenia and leukopenia (usually mild and resolve after discontinuation).

Distinguishing Side Effects from Adverse Reactions: It is important for clinicians to distinguish between side effects (predictable, often dose-related, and generally manageable) and adverse reactions (unexpected, potentially serious, and requiring medical intervention). Diarrhea associated with cefuroxime is typically a side effect related to alterations in gut flora. However, if diarrhea is severe, persistent, or accompanied by fever, abdominal pain, or blood in the stool, it may indicate Clostridioides difficile infection — a serious adverse reaction requiring immediate medical evaluation.

Adverse Effects

While the common side effects of cefuroxime are generally mild and self-limiting, the drug carries a risk of serious adverse effects that all prescribers must recognize and monitor for.

• Serious Hypersensitivity Reactions: Anaphylaxis is the most feared adverse reaction to cefuroxime, though it occurs in fewer than 1 in 1,000 patients. Symptoms include urticaria, angioedema, bronchospasm, hypotension, and cardiovascular collapse. Anaphylaxis typically occurs within minutes to hours of drug administration and requires immediate treatment with epinephrine, airway management, and supportive care. Less severe hypersensitivity reactions include drug fever, serum sickness, and cutaneous vasculitis.
• Severe Dermatologic Reactions: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare but potentially fatal mucocutaneous reactions that have been reported with cefuroxime and other cephalosporins. These reactions are characterized by widespread erythema, bullae formation, and epidermal detachment, often involving the mucous membranes. Early recognition and immediate drug discontinuation are critical, as these reactions carry high mortality rates.
• Clostridioides difficile-Associated Diarrhea (CDAD): CDAD is a significant adverse effect of all antibacterial agents, including cefuroxime. Symptoms range from mild watery diarrhea to fulminant colitis with toxic megacolon, perforation, and death. Risk factors include advanced age, hospitalization, prolonged antibiotic courses, and concurrent use of proton pump inhibitors.
• Hematologic Effects: Cefuroxime can cause hematologic abnormalities including eosinophilia, neutropenia, leukopenia, thrombocytopenia, and, rarely, hemolytic anemia. A positive direct Coombs test may develop during therapy and can interfere with cross-matching of blood. Prolonged prothrombin time has been reported, particularly in patients with vitamin K deficiency or those receiving anticoagulants.
• Hepatic and Renal Effects: Transient elevations in serum transaminases, alkaline phosphatase, and bilirubin have been reported with cefuroxime use. These elevations are typically mild and reversible upon discontinuation of therapy. Rare cases of hepatitis and cholestasis have been reported. Renal effects are uncommon but may include transient increases in BUN and creatinine.
• Neurologic Effects: Seizures have been reported with cefuroxime, particularly in patients with renal impairment who receive standard doses without appropriate interval adjustment. The risk of neurotoxicity is increased in elderly patients, those with underlying CNS disease, and those receiving high doses.
• When to Seek Medical Attention: Patients should be instructed to seek immediate medical attention if they experience any of the following: severe or persistent diarrhea, bloody stools, rash or hives, swelling of the face or throat, difficulty breathing, fever, jaundice, dark urine, or seizures. Prompt recognition and management of these serious adverse reactions can be life-saving.

Drug Interactions

The following table summarizes clinically meaningful drug interactions with cefuroxime. Theoretical interactions of little clinical relevance have been omitted.

Administration Table

Practical administration instructions are essential for patient education and nursing practice. The table below summarizes key administration factors.

Pharmacokinetics

This section consolidates the clinically relevant pharmacokinetic properties of cefuroxime in a professional overview. Detailed explanations of half-life, metabolism, bioavailability, and protein binding are provided in their respective dedicated sections above and are not repeated here.

Absorption and Bioavailability: Cefuroxime axetil is absorbed from the gastrointestinal tract after oral administration, with absorption primarily occurring in the duodenum. Peak serum concentrations are achieved 2–3 hours after oral administration.

Distribution: Cefuroxime has a volume of distribution of 11.1–15.8 L/1.73 m², indicating distribution into total body water and some tissue compartments. The drug achieves therapeutic concentrations in respiratory secretions, skin, soft tissues, and urine — the sites relevant to its approved indications. Penetration into the cerebrospinal fluid is adequate only when the meninges are inflamed, which is why cefuroxime is not a first-line agent for bacterial meningitis.

Metabolism and Elimination: Cefuroxime undergoes minimal hepatic metabolism, with a metabolic stability greater than 95%. The drug is eliminated primarily unchanged by the kidneys, with approximately 95% of a parenteral dose recovered in the urine. Renal clearance involves both glomerular filtration and active tubular secretion, and probenecid inhibits the tubular secretion component.

Special Populations: In elderly patients with reduced creatinine clearance, the elimination half-life is prolonged, but dosage adjustment based solely on age is not required. In patients with renal impairment (CrCl <30 mL/min), the dosage interval must be extended. Hepatic impairment does not significantly alter cefuroxime pharmacokinetics. Pediatric patients have pharmacokinetic profiles similar to adults when dosed on a mg/kg basis.

Special Populations

Pregnancy: Cefuroxime is classified as Pregnancy Category B. Animal reproduction studies have not demonstrated evidence of impaired fertility or harm to the fetus, but adequate and well-controlled studies in pregnant women are lacking. Cefuroxime should be used during pregnancy only if clearly needed.

Lactation: Cefuroxime is excreted in human milk in small quantities. A case of diarrhea was reported in 2.6% of cefuroxime-exposed infants. The American Academy of Pediatrics considers cefuroxime compatible with breastfeeding, though monitoring of the infant for diarrhea or thrush is prudent.

Pediatrics: Cefuroxime axetil is approved for use in pediatric patients 3 months to 12 years (oral suspension) and 13 years and older (tablets). The safety and efficacy of cefuroxime in neonates (younger than 3 months) have not been established. Weight-based dosing is used for pediatric patients, with maximum daily dose limits to prevent toxicity.

Older Adults: Clinical studies of cefuroxime axetil did not include sufficient numbers of subjects aged 65 and older to determine whether they respond differently from younger subjects. However, the prolonged half-life observed in elderly patients with reduced renal function suggests that renal function — not age alone — should guide dosing decisions.

Renal Impairment: Renal impairment has the most significant impact on cefuroxime pharmacokinetics. Dosage interval adjustment is required for patients with creatinine clearance less than 30 mL/min. For CrCl 10–29 mL/min, the standard dose should be given every 24 hours; for CrCl <10 mL/min without hemodialysis, every 48 hours.

Hepatic Impairment: Hepatic impairment does not significantly alter the pharmacokinetics of cefuroxime because the drug undergoes minimal hepatic metabolism. However, transient liver enzyme elevations have been observed, and monitoring of hepatic function may be appropriate in patients with underlying liver disease.

Monitoring

• Clinical Response: The most important monitoring parameter is the patient’s clinical response to therapy. Improvement in signs and symptoms of infection — such as resolution of fever, reduction in pain, and improvement in functional status — should be assessed within 48–72 hours of initiating therapy. Lack of clinical improvement may indicate the need for reassessment of the diagnosis, culture and susceptibility testing, or a change in antibiotic therapy.
• Laboratory Parameters: In patients with pre-existing renal impairment or those receiving concomitant nephrotoxic drugs, monitoring of serum creatinine and BUN is recommended. In patients with hepatic disease, periodic monitoring of liver enzymes (AST, ALT, alkaline phosphatase, bilirubin) may be appropriate. Complete blood count with differential may be indicated in patients receiving prolonged therapy to monitor for hematologic effects.
• Microbiological Response: When cultures are obtained before initiating therapy, repeat cultures may be useful to confirm eradication of the pathogen, particularly in infections such as streptococcal pharyngitis where eradication is important to prevent sequelae.
• Adverse Reaction Monitoring: Patients should be monitored for signs of hypersensitivity reactions (rash, urticaria, angioedema), CDAD (severe or persistent diarrhea), and neurotoxicity (confusion, seizures). In patients with renal impairment, vigilance for signs of drug accumulation is particularly important.

Clinical Perspective

From a clinical standpoint, cefuroxime occupies a valuable niche in the antibiotic armamentarium. It is not the most potent agent against any single organism, but its balanced spectrum of activity against common community-acquired respiratory and skin pathogens — including beta-lactamase-producing H. influenzae and M. catarrhalis — makes it a reliable choice for empirical therapy when culture data are pending.

Clinicians may prefer cefuroxime when treating infections likely to be caused by a mix of gram-positive and gram-negative organisms, such as acute bacterial sinusitis or acute exacerbations of chronic bronchitis. It is also a valuable option for early Lyme disease in patients who cannot take doxycycline (such as pregnant women or young children) or when doxycycline is not tolerated.

Situations where clinicians may prefer alternatives include infections suspected to be caused by MRSA, Pseudomonas aeruginosa, or ESBL-producing organisms — all of which are resistant to cefuroxime. In these cases, broader-spectrum agents or combination therapy may be necessary. Additionally, cefuroxime is not appropriate for bacterial meningitis due to inadequate CNS penetration.

Antimicrobial stewardship considerations are paramount. Cefuroxime is classified in the WHO AWaRe “Watch” group, meaning it should be used judiciously to preserve its effectiveness. Clinicians should obtain cultures whenever possible, narrow therapy based on susceptibility results, and avoid using cefuroxime for conditions where narrower-spectrum agents (such as amoxicillin or penicillin) would be equally effective.

Patient-specific considerations include renal function (dose adjustment required for CrCl <30 mL/min), allergy history (caution in penicillin-allergic patients), and the ability to take oral medications. Interpretation of treatment response should occur within 48–72 hours; if the patient is not improving, reassessment of the diagnosis, culture data, and therapeutic choice is warranted.

Question. What is cefuroxime used for?

Answer : Cefuroxime is used to treat a wide range of bacterial infections, including pharyngitis/tonsillitis, acute bacterial otitis media, sinusitis, acute exacerbations of chronic bronchitis, uncomplicated skin and skin-structure infections, uncomplicated urinary tract infections, uncomplicated gonorrhea, early Lyme disease, and impetigo.

Question. What is cefuroxime axetil used for?

Answer : Cefuroxime axetil is the oral prodrug form of cefuroxime, used for the same FDA-approved indications as the parent drug. It is particularly useful for outpatient treatment of respiratory tract infections, skin infections, and early Lyme disease.

Question. How does cefuroxime work?

Answer : Cefuroxime works by binding to penicillin-binding proteins (PBPs) in the bacterial cell wall, inhibiting peptidoglycan cross-linking and causing bacterial cell lysis and death. It is bactericidal and has activity in the presence of some beta-lactamases.

Question. How long does cefuroxime stay in the body?

Answer : The elimination half-life of cefuroxime is approximately 1–2 hours in patients with normal renal function. This means the drug is largely eliminated within 6–12 hours after a dose. In patients with renal impairment, the half-life is prolonged.

Question. What is the half-life of cefuroxime?

Answer : The mean serum half-life of cefuroxime is approximately 70 minutes (1.2 hours) in healthy adults. In elderly patients with reduced creatinine clearance, it may be prolonged to 3.5 hours.

Question. What are the common side effects of cefuroxime?

Answer : Common side effects include diarrhea (1–10%), nausea, vomiting, abdominal cramps, headache, dizziness, and vaginal candidiasis.

Question. What are the serious adverse effects of cefuroxime?

Answer : Serious adverse effects include anaphylaxis, Stevens-Johnson syndrome, toxic epidermal necrolysis, Clostridioides difficile-associated diarrhea, seizures (particularly in renal impairment), hemolytic anemia, and neutropenia.

Question. Is cefuroxime FDA approved?

Answer : Yes, cefuroxime axetil was initially approved by the FDA in 1987 and is approved for multiple indications including pharyngitis, otitis media, sinusitis, bronchitis exacerbations, skin infections, UTI, gonorrhea, early Lyme disease, and impetigo.

Question. What is cefuroxime 500 mg used for?

Answer : Cefuroxime 500 mg is used for more severe or resistant infections, including acute exacerbations of chronic bronchitis, uncomplicated skin infections, and early Lyme disease. It is also used when the 250 mg dose may be insufficient due to organism susceptibility or patient factors.

Question. What is cefuroxime 250 mg used for?

Answer : Cefuroxime 250 mg is the standard dose for mild-to-moderate pharyngitis/tonsillitis, acute bacterial maxillary sinusitis, and uncomplicated urinary tract infections in adults and adolescents.

Question. Can cefuroxime be used during pregnancy?

Answer : Cefuroxime is Pregnancy Category B. It should be used during pregnancy only if clearly needed, as there are limited data on its use in pregnant women.

Question. Can cefuroxime be used while breastfeeding?

Answer : Cefuroxime is excreted in human milk in small quantities. Caution is recommended, and a decision should be made whether to discontinue breastfeeding or the drug, taking into account the benefit of breastfeeding to the infant and the benefit of therapy to the mother.

Question. Does cefuroxime interact with alcohol?

Answer : No disulfiram-like reaction has been reported with cefuroxime. However, alcohol may worsen gastrointestinal side effects such as nausea and diarrhea. Moderation is advised.

Question. What medicines interact with cefuroxime?

Answer : Probenecid increases cefuroxime levels by inhibiting renal tubular secretion and should not be co-administered. Loop diuretics and aminoglycosides may increase nephrotoxicity risk. Warfarin effects may be potentiated.

Question. What happens if a dose is missed?

Answer : Take the missed dose as soon as remembered unless it is almost time for the next dose. Do not double doses to make up for a missed one.

Question. How should cefuroxime be administered?

Answer : Tablets can be taken with or without food. The oral suspension should be taken with food to enhance absorption. Complete the full course even if symptoms improve.

Question. Does renal impairment require dose adjustment?

Answer : Yes. For creatinine clearance less than 30 mL/min, the dosage interval should be extended to every 24 hours (CrCl 10–29) or every 48 hours (CrCl <10).

Question. Does hepatic impairment affect cefuroxime use?

Answer : Hepatic impairment does not significantly alter cefuroxime pharmacokinetics since the drug undergoes minimal hepatic metabolism. However, transient liver enzyme elevations may occur.

Question. Is cefuroxime safe for children?

Answer : Cefuroxime axetil oral suspension is approved for pediatric patients 3 months to 12 years. Tablets are approved for patients 13 years and older who can swallow tablets whole.

Question. Is cefuroxime appropriate for older adults?

Answer : Yes, but dosing should be based on renal function rather than age. Elderly patients with reduced creatinine clearance may require dosage interval adjustment.

Question. What should clinicians monitor during cefuroxime therapy?

Answer : Monitor clinical response, renal function (in at-risk patients), liver enzymes (in hepatic disease), and signs of adverse reactions such as rash, severe diarrhea, or neurotoxicity.

Question. What are alternatives to cefuroxime?

Answer : Alternatives depend on the infection. Amoxicillin, amoxicillin-clavulanate, doxycycline, and azithromycin are alternatives for respiratory infections. Ceftriaxone is preferred over cefuroxime for gonorrhea.

Question. What are the major contraindications to cefuroxime?

Answer : Known hypersensitivity to cefuroxime or other beta-lactam antibiotics is the primary contraindication. Caution is advised in patients with penicillin allergy.

Question. How does resistance affect cefuroxime use?

Answer : Resistance to cefuroxime occurs through beta-lactamase production (including ESBLs), altered PBPs, decreased permeability, and efflux pumps. Susceptibility testing should guide use when possible.

Question. When should medical attention be sought during cefuroxime therapy?

Answer : Seek immediate medical attention for severe or persistent diarrhea, bloody stools, rash or hives, facial swelling, difficulty breathing, fever, jaundice, dark urine, or seizures.

5 Authentic Studies

Study 1

Citation: Foord RD. Cefuroxime: Human Pharmacokinetics. Antimicrob Agents Chemother. 1976;9(5):741-747. PMID: 949172.

Study Type: Phase 1 pharmacokinetic study.

Population: 44 normal male volunteers.

Intervention/Exposure: Single doses of cefuroxime administered intramuscularly (0.25, 0.5, 0.75, or 1.0 g to 33 volunteers) or intravenously (0.25, 0.5, or 1.0 g to 9 volunteers).

Main Outcome: Serum concentration-time profiles, half-life, protein binding, volume of distribution, and urinary recovery.

Key Findings: Mean peak serum concentrations after IM administration ranged from 14.8 to 40.0 μg/mL. The mean ultimate serum half-life was 70 minutes, mean protein binding was 33%, metabolic stability exceeded 95%, and mean urinary recovery was at least 95%. Approximately 43–54% of the drug was secreted through renal tubules.

Clinical Significance: This foundational study established the core pharmacokinetic parameters of cefuroxime that continue to guide dosing recommendations today. The high urinary recovery and renal tubular secretion profile explain why dosage adjustment is essential in renal impairment.

Important Limitation: The study was conducted in healthy male volunteers only, so findings may not be fully generalizable to women, elderly patients, or those with comorbidities.

Study 2

Citation: Cefuroxime axetil FDA prescribing information, Section 14.1 Clinical Studies. DailyMed, National Library of Medicine. Updated March 2026.

Study Type: Randomized, controlled clinical trial.

Population: 317 adult subjects (132 in the U.S., 185 in South America) with acute bacterial maxillary sinusitis confirmed by sinus puncture and radiographic evidence.

Intervention/Exposure: Cefuroxime axetil 250 mg twice daily.

Comparator: Oral antimicrobial containing a specific beta-lactamase inhibitor.

Main Outcome: Clinical success (cure + improvement) at end of treatment.

Key Findings: Clinical success rates were 65% (U.S.) and 77% (South America) for cefuroxime axetil. Microbiology data demonstrated effectiveness against Streptococcus pneumoniae (83% eradication) and non-beta-lactamase-producing Haemophilus influenzae (67% eradication).

Clinical Significance: This trial provided the pivotal evidence for FDA approval of cefuroxime axetil in acute bacterial maxillary sinusitis and clarified its spectrum of activity against specific pathogens.

Important Limitation: Insufficient numbers of beta-lactamase-producing H. influenzae and Moraxella catarrhalis isolates were obtained to adequately evaluate effectiveness against these organisms.

Study 3

Citation: Cefuroxime axetil FDA prescribing information, Section 14.2 Clinical Studies. DailyMed, National Library of Medicine. Updated March 2026.

Study Type: Two randomized, controlled clinical trials.

Population: 355 adult subjects (181 cefuroxime axetil, 174 doxycycline) with physician-documented erythema migrans.

Intervention/Exposure: Cefuroxime axetil 500 mg twice daily for 20 days.

Comparator: Doxycycline.

Main Outcome: Success in treating early Lyme disease at 1 month and prevention of late Lyme disease sequelae at 1 year.

Key Findings: Cefuroxime axetil and doxycycline were both effective in preventing the development of sequelae of late Lyme disease. Diagnosis of early Lyme disease was validated in 79% of subjects by blinded expert reading of photographs and serologic confirmation.

Clinical Significance: These trials established cefuroxime axetil as an effective alternative to doxycycline for early Lyme disease, particularly important for patients who cannot take doxycycline (pregnant women, children under 8 years).

Important Limitation: The trials enrolled only adults; efficacy in children was supported by extrapolation and smaller studies.

Study 4

Citation: Real-world Study on the Efficacy and Safety of Cefuroxime Sodium: A Drug Procured Through National Centralized Volume-based Procurement. Published 2025.

Study Type: Real-world observational study.

Population: Patients receiving cefuroxime sodium for perioperative prophylaxis.

Intervention/Exposure: Centralized procurement cefuroxime sodium.

Comparator: Original research drug (brand-name cefuroxime).

Main Outcome: Clinical efficacy, safety, and cost.

Key Findings: The centralized procurement group incurred significantly lower costs compared to the original research drug while maintaining comparable efficacy and safety profiles.

Clinical Significance: This study demonstrates that cost-effective alternatives to brand-name cefuroxime can provide equivalent clinical outcomes, supporting healthcare system sustainability without compromising patient care.

Important Limitation: Observational design introduces potential confounding; randomized controlled trials would provide stronger evidence.

Study 5

Citation: Cefuroxime axetil FDA prescribing information, Section 12.4 Microbiology. DailyMed, National Library of Medicine. Updated March 2026.

Study Type: Comprehensive microbiological surveillance and susceptibility analysis.

Population: Clinical isolates from various infection sites.

Intervention/Exposure: In vitro susceptibility testing of cefuroxime against gram-positive, gram-negative, and anaerobic bacteria.

Main Outcome: Minimum inhibitory concentration (MIC) distributions and susceptibility rates.

Key Findings: Cefuroxime demonstrated activity against methicillin-susceptible S. aureus, S. pneumoniae, S. pyogenes, E. coli, K. pneumoniae, H. influenzae, H. parainfluenzae, M. catarrhalis, N. gonorrhoeae, and B. burgdorferi. Most ESBL-producing and carbapenemase-producing isolates were resistant.

Clinical Significance: This comprehensive susceptibility data provides the evidence base for empiric prescribing and highlights the importance of local resistance surveillance to guide appropriate use.

Important Limitation: In vitro susceptibility does not always predict clinical efficacy; site of infection and host factors influence outcomes.

Authentic References

1. Cefuroxime Axetil Tablets — FDA Prescribing Information. DailyMed, National Library of Medicine. Updated March 18, 2026.
2. CEFTIN (cefuroxime axetil) Tablets and Oral Suspension — Prescribing Information. Drugs.com. Updated March 24, 2026.
3. Cefuroxime for Injection, USP — FDA Prescribing Information. DailyMed, National Library of Medicine. Updated December 9, 2024.
4. Foord RD. Cefuroxime: Human Pharmacokinetics. Antimicrobial Agents and Chemotherapy. 1976;9(5):741-747. PMID: 949172.
5. Cefuroxime Axetil — DrugBank. https://go.drugbank.com/drugs/DB01112
6. Cefuroxime — StatPearls. National Library of Medicine. Updated January 11, 2024.
7. Cefuroxime Axetil — AHFS Drug Information. American Society of Health-System Pharmacists.
8. Cefuroxime — WHO AWaRe Classification of Antibiotics. World Health Organization. 2022.
9. Cefuroxime — LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases.
10. Cefuroxime Use During Pregnancy and Breastfeeding — Drugs.com. Updated October 23, 2025.
11. Zinnat (cefuroxime axetil) — Summary of Product Characteristics. Electronic Medicines Compendium. Updated July 11, 2023.
12. Zinacef (cefuroxime sodium) — Summary of Product Characteristics. Electronic Medicines Compendium. Updated July 8, 2024.
13. Cefuroxime — Pediatric Dosing. PedMed.
14. Cefuroxime Axetil — Renal Impairment Dosing. MedLibrary.
15. Real-world Study on the Efficacy and Safety of Cefuroxime Sodium: A Drug Procured Through National Centralized Volume-based Procurement. 2025.
16. Clostridioides difficile-Associated Diarrhea — FDA Prescribing Information. DailyMed.
17. Cefuroxime — ATC Code J01DC02. WHO Collaborating Centre for Drug Statistics Methodology.
18. Cefuroxime Axetil — Drug Interaction Report. Drugs.com.
19. Cefuroxime — Toxicity and Overdosage. Medsafe New Zealand.
20. Cefuroxime — Antimicrobial Stewardship Resources. Centers for Disease Control and Prevention (CDC).
21. Cefuroxime — NIH DailyMed Drug Label Archives. National Library of Medicine.

Medical Information Disclaimer: The information provided in this article is for educational and informational purposes only and is intended for healthcare professionals, medical students, and informed general readers. It does not constitute medical advice, diagnosis, or treatment recommendations. Cefuroxime is a prescription medication that should only be used under the supervision of a qualified healthcare provider. Treatment decisions, including dose selection, duration, and adjustments, depend on the patient’s diagnosis, age, renal and hepatic function, interacting medicines, susceptibility data where relevant, and clinician judgment. Readers should not use this information to self-medicate or to make clinical decisions without appropriate professional consultation. If you have a medical condition or are experiencing symptoms of infection, seek evaluation from a qualified healthcare professional. The authors and publishers of this article do not assume any liability for any adverse effects or consequences resulting from the use or misuse of the information provided herein.

If you are exploring the pharmacology of everyday pain relievers alongside antibiotics, you may be surprised by how much their safety profiles differ. For a suspenseful, evidence-based breakdown, explore Facts of Ibuprofen Uses, Dosage and Side Effects — but keep your clinical focus on cefuroxime first.

For authentic and engaging information about the world’s different religions, visit ssthem.com for religious studies and discover well-organized, informative content.

For online earning ideas, freelancing, affiliate marketing, YouTube, Facebook monetization, and AI tips, visit ssthem.xyz for online earning and WhatsApp group links.

For health, beauty, fitness, and everyday wellness articles, explore ssthem.net for health and wellness content.